Characterization of FGFR1 locus in sqNSCLC reveals a broad and heterogeneous amplicon

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Rooney, Claire ^a   Geh, Catherine ^a   Williams, Victoria ^a   Heuckmann, Johannes M ^b   Menon, Roopika ^b   Schneider, Petra ^b   Al Kadhimi, Katherine ^a   Dymond, Michael ^a   Smith, Neil R ^a   Baker, Dawn ^a   French, Tim ^a   Smith, Paul D ^a   Harrington, Elizabeth A ^a   Barrett, J Carl ^a   Kilgour, Elaine ^a  

^a ASTRAZENECA   (United Kingdom)

^b NEO New Oncology GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 4547; BAG4 PROTEIN; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; LSM1 PROTEIN; MESSENGER RNA; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; WHSC1L1 PROTEIN; BENZAMIDE DERIVATIVE; FGFR1 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRAZOLE DERIVATIVE;

AMPLICON; ARTICLE; CANCER TISSUE; CHROMOSOME 8P; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER CELL LINE; PREDICTION; PROTEIN EXPRESSION; SQUAMOUS CELL LUNG CARCINOMA; TISSUE FIXATION; UPREGULATION; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CHROMOSOME 8; DRUG EFFECTS; GENE AMPLIFICATION; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; PROCEDURES; REPRODUCIBILITY; TUMOR CELL LINE;

BENZAMIDES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 8; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PIPERAZINES; PYRAZOLES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REPRODUCIBILITY OF RESULTS;

EID: 84960532558     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149628     Document Type: Article

References (26)

1. De Santis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer Treatment and Survivorship Statistics, 2014. Ca-Cancer J Clin. 2014;64(4):252-71. doi: 10.3322/Caac.21235 WOS:000339475900004. PMID: 24890451
2. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology. 2010;11(2):121-8. doi: 10.1016/S1470-2045 (09) 70364-XPMID: 20022809.
3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lungcancerwith mutated EGFR. The New England journal of medicine. 2010;362(25):2380-8. doi: 10.1056/NEJMoa0909530 PMID: 20573926.
4. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet Oncology. 2011;12(11):1004-12. doi: 10.1016/S1470-2045 (11) 70232-7 PMID: 21933749; PubMed Central PMCID: PMC3328296.
5. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015. doi: 10.1056/NEJMoa1504627 PMID: 26028407.
6. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science translational medicine. 2010;2(62):62ra93. Epub2010/12/17. doi: 10.1126/scitranslmed. 3001451 PMID: 21160078; PubMed Central PMCID: PMCPmc3990281.
7. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PloSone. 2011;6(6):e20351. Epub 2011/06/15. doi: 10.1371/journal.pone.0020351 PMID: 21666749; PubMed Central PMCID: PMCPmc3110189.
8. Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley interdisciplinary reviews Developmental biology. 2015;4(3):215-66. doi: 10.1002/wdev. 176 PMID: 25772309; PubMed Central PMCID: PMC4393358.
9. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nature reviews Cancer. 2010;10(2):116-29. doi: 10.1038/nrc2780 PMID: 20094046.
10. Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18(24):6658-67. Epub 2012/10/20. doi: 10.1158/1078-0432.ccr-12-2694 PMID: 23082000.
11. Kilgour E, Ferry D, Saggese M, Arkenau HT, Rooney C, Smith NR, et al. Exploratory biomarkeranalysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. ASCO Annual Meeting: J Clin Oncol; 2014. p. suppl:; abstr 11010.
12. Wolf J, Lo Russo PM, Camidge DR, Perez JM, Taberno J, Hidalgo M, et al. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research 2012.
13. Malchers F, Dietlein F, Schottle J, Lu X, Nogova L, Albus K, et al. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer discovery. 2014;4(2):246-57. Epub 2013/12/05. doi: 10.1158/2159-8290.cd-13-0323 PMID: 24302556.
14. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(16):9440-5. doi: 10.1073/pnas. 1530509100 PMID: 12883005; PubMed Central PMCID: PMC170937.
15. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics. 2007;23(6):657-63. doi: 10.1093/bioinformatics/btl646 PMID: 17234643.
16. Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, et al. FGFR1 mRNAand Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014. Epub 2014/04/29. doi: 10.1158/1078-0432.ccr-13-3060 PMID: 24771645.
17. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nature biotechnology. 2008;26(3):317-25. Epub 2008/02/19. doi: 10.1038/nbt1385 PMID: 18278033.
18. Malkov VA, Serikawa KA, Balantac N, Watters J, Geiss G, Mashadi-Hossein A, et al. Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter Assay System. BMC research notes. 2009;2:80. doi: 10.1186/1756-0500-2-80 PMID: 19426535; PubMed Central PMCID: PMC2688518.
19. Reis PP, Waldron L, Goswami RS, Xu W, Xuan Y, Perez-Ordonez B, et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC biotechnology. 2011;11:46. Epub 2011/05/10. doi: 10.1186/1472-6750-11-46 PMID: 21549012; PubMed Central PMCID: PMCPmc3103428.
20. Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rouge C, et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Molecular cancer research: MCR. 2005;3(12):655-67. doi: 10. 1158/1541-7786. MCR-05-0128 PMID: 16380503.
21. Yang ZQ, Liu G, Bollig-Fischer A, Giroux CN, Ethier SP. Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer research. 2010;70(21):8487-97. doi: 10.1158/0008-5472. CAN-10-1013 PMID: 20940404; PubMed Central PMCID: PMC3089754.
22. Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer research. 2006;66(24):11632-43. doi: 10.1158/0008-5472. CAN-06-2946 PMID: 17178857.
23. Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31(6):731-7. doi: 10.1200/JCO.2012.43.8622 PMID: 23182986.
24. Kotani H, Ebi H, Kitai H, Nanjo S, Kita K, Huynh TG, et al. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with lowFGFR1 protein expression. Oncogene. 2015. doi: 10.1038/onc.2015.426 PMID: 26549034.
25. Kohler LH, Mireskandari M, Knosel T, Altendorf-Hofmann A, Kunze A, Schmidt A, et al. FGFR1 expression and gene copy numbers in human lung cancer. Virchows Archiv: an international journal of pathology. 2012;461(1):49-57. doi: 10.1007/s00428-012-1250-y PMID: 22648708.
26. Goke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, et al. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015;21(19):4356-64. doi: 10.1158/1078-0432. CCR-14-3357 PMID: 26015511; PubMed Central PMCID: PMC4592392.